34
PATHOPHYSIOLOGICAL AND CLINICAL MANIFESTATIONS OF DIABETIC
CARDIOMYOPATHY IN TYPE 2 DIABETES UNDER INTENSE HEAT
EXPOSURE: AN IN-DEPTH THERAPEUTIC OUTLOOK
Beshimov A.Ya.
Bukhara State Medical University
https://doi.org/10.5281/zenodo.15755386
Relevance:
Diabetic cardiomyopathy (DCM) is increasingly recognized as a distinct cardiovascular
complication of type 2 diabetes mellitus (T2DM). In hot climate regions, thermal stress
exacerbates metabolic dysfunction and cardiovascular instability, leading to early onset and
aggressive progression of DCM.
Objective:
To examine the clinical, functional, and metabolic features of DCM in patients with
T2DM living in hot climates, and to propose evidence-based strategies for optimizing
metabolic and cardiovascular therapy under heat stress conditions.
Key Findings:
Early development of diastolic dysfunction and preserved ejection fraction heart failure
is prevalent in thermally stressed patients.\n- Hot climates intensify insulin resistance,
oxidative stress, and systemic inflammation, aggravating myocardial injury.\n- Electrolyte
imbalance, dehydration, and autonomic dysfunction are common complications.\n-
Therapeutic recommendations must account for altered pharmacokinetics, fluid balance, and
lifestyle constraints.
Practical Significance:
The results suggest the need for climate-specific treatment algorithms that include
advanced glycemic monitoring, cardiovascular protection, antioxidant therapy, and patient
education adapted to environmental risks.
Perspective:
Further research is warranted to develop predictive tools integrating climatic, genetic,
and metabolic data for personalized management of DCM in hot environments.
References:
Используемая литература:
Foydalanilgan adabiyotlar:
1.
Trachanas K., Sideris S., Aggeli C., Poulidakis E., Gatzoulis K., Tousoulis D., et al. Diabetic
cardiomyopathy: from pathophysiology to treatment. Hellenic J Cardiol.2014;55:411- 421.
PMID:
2.
Lundbaek K. Diabetic angiopathy. A specific vascular disease. Lancet. 1954;263:377-
https://doi.org/10.1016/S0140-6736(54)90924-1
3.
Rubler S., Dlugash J., Yuceoglu Y.Z., Kumral T., Branwood A.W., Grishman A., et al. New
type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol.
1972;30:595- 602.
https://doi.org/10.1016/0002-9149(72)90595-4
4.
Kannel W.B., Hjortland M., Castelli W.P. Role of diabetes in congestive heart failure; the
35
5.
Penpargkul S., Fein F., Sonnenblick E.H., Scheuer J. Depressed cardiac sarcoplasmic
reticular
function
from
diabetic
rats.
J
Mol
Cell
Cardiol.
1981;13:303-
https://doi.org/10.1016/0022-2828(81)90318-7
6.
Trost S.U., Belke D.D., Bluhm W.F., Meyer M., Swanson E., Dillmann W.H. Overexpression
of the sarcoplasmic reticulum Ca(2+)-ATPase improves myocardial contractility in diabetic
cardiomyopathy. Diabetes. 2002;51:1166-71.
https://doi.org/10.2337/diabetes.51.4.1166
7.
Current and Future Therapies. Beyond Glycemic Control. Front Physiol.
https://doi.org/10.3389/fphys.2018.01514
8.
Lorenzo-Almorós A., Tuñón J., Orejas M., Cortés M., Egido J., Lorenzo Ó. Diagnostic
approaches
for
diabetic
cardiomyopathy.
Cardiovasc
Diabetol.
https://doi.org/10.1186/s12933-017-0506-x
9.
Marcinkiewicz A., Ostrowski S., Drzewoski J. Can the onset of heart failure be delayed by
treating
diabetic
cardiomyopathy?
Diabetol
Metab
Syndr.
https://doi.org/10.1186/s13098-017-0219-z
10.
Lee W.S., Kim J. Diabetic cardiomyopathy: where we are and where we are going. Korean
J Intern Med. 2017;32(3):404- 421.
https://doi.org/10.3904/kjim.2016.208.
11.
Dillmann
W.H.
Diabetic
Cardiomyopathy.
Circ
Res.
2019;124(8):1160-
